We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $10.2B
1-Year Est. Return 149.19%
This Fund
S&P 500
This Quarter Est. Return
+24.53%
1 Year Est. Return
+149.19%
3 Year Est. Return
+425.03%
5 Year Est. Return
+775.33%
10 Year Est. Return
+45,729.2%
AUM
$2.89B
AUM Growth
+$580M
Cap. Flow
+$390M
Cap. Flow %
13.47%
Top 10 Hldgs %
71.19%
Holding
39
New
7
Increased
11
Reduced
4
Closed
4

Top Buys

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$85.1M
2
ATNX
Athenex, Inc. Common Stock
ATNX
+$63.8M
3
IMMU
Immunomedics Inc
IMMU
+$49.4M
4
ADVM
Adverum Biotechnologies
ADVM
+$29M
5
PTCT icon
PTC Therapeutics
PTCT
+$27M

Top Sells

Rank Stock Value
1
MDCO
Medicines Co
MDCO
+$20.8M
2
ASMB icon
Assembly Biosciences
ASMB
+$17.7M
3
ESTA icon
Establishment Labs
ESTA
+$11.4M
4
INDP icon
Indaptus Therapeutics
INDP
+$9.46M
5
AMRN
Amarin Corp
AMRN
+$9.16M

Sector Composition

Rank Sector Weight
1 Healthcare 88.57%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRTX
1
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$398M 13.75%
3,862,500
– –
IMMU
2
DELISTED
Immunomedics Inc
IMMU
$291M 10.07%
21,000,000
+3,285,539
+19% +$49.4M
IOVA icon
3
Iovance Biotherapeutics
IOVA
$2.03B
$264M 9.11%
10,752,585
+221,723
+2% +$3.34M
ASND icon
4
Ascendis Pharma A/S
ASND
$16.6B
$227M 7.84%
1,970,000
+175,000
+10% +$20.9M
SRPT icon
5
Sarepta Therapeutics
SRPT
$1.64B
$213M 7.35%
1,400,000
+205,000
+17% +$24.9M
BMRN icon
6
BioMarin Pharmaceuticals
BMRN
$11.9B
$181M 6.26%
2,115,000
+995,000
+89% +$85.1M
AMRN
7
Amarin Corp
AMRN
$300M
$145M 5.03%
375,000
-25,000
-6% -$9.16M
FOLD
8
DELISTED
Amicus Therapeutics
FOLD
$125M 4.31%
10,000,000
+500,000
+5% +$6.34M
ARGX icon
9
argenx
ARGX
$54.9B
$119M 4.11%
840,000
– –
ZGNX
10
DELISTED
Zogenix, Inc.
ZGNX
$96.8M 3.34%
2,025,000
+110,000
+6% +$4.43M
HZNP
11
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$96.2M 3.33%
4,000,000
– –
ARRY
12
DELISTED
Array Biopharma Inc
ARRY
$92.7M 3.2%
2,000,000
– –
ATNX
13
DELISTED
Athenex, Inc. Common Stock
ATNX
$91.2M 3.15%
+230,250
New +$63.8M
TCDA
14
DELISTED
Tricida, Inc. Common Stock
TCDA
$86.8M 3%
2,200,000
+500,000
+29% +$17.6M
MYOK
15
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$68.9M 2.38%
1,375,000
+375,000
+38% +$18.3M
GBT
16
DELISTED
Global Blood Therapeutics, Inc.
GBT
$50M 1.73%
950,000
– –
ADVM
17
DELISTED
Adverum Biotechnologies
ADVM
$41.6M 1.44%
+350,000
New +$29M
MDGL icon
18
Madrigal Pharmaceuticals
MDGL
$12.4B
$37.7M 1.3%
360,000
+50,000
+16% +$5.36M
ACAD icon
19
Acadia Pharmaceuticals
ACAD
$4.45B
$35.4M 1.22%
1,325,000
– –
BDSI
20
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$34.5M 1.19%
7,424,867
– –
MDCO
21
DELISTED
Medicines Co
MDCO
$33.7M 1.17%
925,000
-637,000
-41% -$20.8M
PTCT icon
22
PTC Therapeutics
PTCT
$6.12B
$30.8M 1.06%
+684,000
New +$27M
ALLO icon
23
Allogene Therapeutics
ALLO
$607M
$30.3M 1.05%
1,128,594
– –
XENE icon
24
Xenon Pharmaceuticals
XENE
$6.16B
$23.7M 0.82%
2,400,000
– –
CBAY
25
DELISTED
Cymabay Therapeutics
CBAY
$19.3M 0.67%
2,700,000
+1,975,000
+272% +$22.4M
1
2

Similar funds

IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $10.2B AUM 16.58% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
LWCFA
Loring Wolcott & Coolidge Fiduciary Advisors Boston, Massachusetts $9.98B AUM 4.97% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Avoro Capital Advisors's Q2 2019 Portfolio in Review

As of Q2 2019, Avoro Capital Advisors held 39 positions worth $2.89B, up 25% from $2.31B the previous quarter. Its ten largest holdings account for 71% of the portfolio.

Avoro Capital Advisors deployed $390M of net new capital in Q2 2019, opening 7 new positions and adding to 11 existing holdings. Its largest new stake was Athenex, Inc. Common Stock: 230,250 shares worth $91.2M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 83% a quarter earlier.

On the sell side, the largest reduction was Medicines Co, an estimated $20.8M trimmed.

  • Avoro Capital Advisors's largest Q2 2019 buy was Athenex, Inc. Common Stock: 230,250 shares worth $91.2M.
  • Avoro Capital Advisors added most to BioMarin Pharmaceuticals in Q2 2019, an estimated $85.1M increase.
  • Avoro Capital Advisors's biggest Q2 2019 reduction was Medicines Co, cutting an estimated $20.8M.
  • Avoro Capital Advisors fully exited Assembly Biosciences in Q2 2019, selling an estimated $17.7M.
  • Avoro Capital Advisors's ten largest holdings make up 71% of its $2.89B portfolio in Q2 2019.
  • Avoro Capital Advisors opened 7 new positions and closed 4 in Q2 2019.
  • Avoro Capital Advisors's portfolio value rose 25% quarter-over-quarter to $2.89B.

Based on Avoro Capital Advisors's 13F filing for Q2 2019, filed 14 Aug 2019.